[en] Objectives: Zeel T (Ze14) is a multicomponent medicinal product. Initial preclinical data suggested a preventive effect on cartilage degradation. Clinical observational studies demonstrated that Ze14 reduced symptoms of osteoarthritis (OA), including stiffness and pain. This study aimed to explore these effects further to better understand the mode of action of Ze14 on human OA chondrocytes in vitro.
Methods: Primary chondrocytes were obtained from the knees of 19 OA patients and cultured either as monolayers or in alginate beads. The cultures were treated with 20% or 10% (v/v) Ze14 or placebo. For RNA-seq, reads were generated with Illumina NextSeq5000 sequencer and aligned to the human reference genome (UCSC hg19). Differential expression analysis between Ze14 and placebo was performed in R using the DESeq2 package. Protein quantification by ELISA was performed on selected genes from the culture medium and/or the cellular fractions of primary human OA chondrocyte cultures.
Results: In monolayer cultures, Ze14 20% (v/v) significantly modified the expression of 13 genes in OA chondrocytes by at least 10% with an adjusted p-value < 0.05: EGR1, FOS, NR4A1, DUSP1, ZFP36, ZFP36L1, NFKBIZ, and CCN1 were upregulated and ATF7IP, TXNIP, DEPP1, CLEC3A, and MMP13 were downregulated after 24 h Ze14 treatment. Ze14 significantly increased (mean 2.3-fold after 24 h, p = 0.0444 and 72 h, p = 0.0239) the CCN1 protein production in human OA chondrocytes. After 72 h, Ze14 significantly increased type II collagen pro-peptide production by mean 27% (p = 0.0147). For both time points CCN1 production by OA chondrocytes was correlated with aggrecan (r = 0.66, p = 0.0004) and type II collagen pro-peptide (r = 0.64, p = 0.0008) production. In alginate beads cultures, pro-MMP-13 was decreased by Ze14 from day 7–14 (from −16 to −25%, p < 0.05) and from day 17–21 (−22%, p = 0.0331) in comparison to controls.
Conclusion: Ze14 significantly modified the expression of DUSP1, DEPP1, ZFP36/ZFP36L1, and CLEC3A, which may reduce MMP13 expression and activation. Protein analysis confirmed that Ze14 significantly reduced the production of pro-MMP-13. As MMP-13 is involved in type II collagen degradation, Ze14 may limit cartilage degradation. Ze14 also promoted extracellular matrix formation arguably through CCN1 production, a growth factor well correlated with type II collagen and aggrecan production.
Research center :
d‐BRU - Dental Biomaterials Research Unit - ULiège [BE]
Disciplines :
Rheumatology
Author, co-author :
Sanchez, Christelle ; Université de Liège - ULiège > Département des sciences de la motricité > musculoSkeletal Innovative research Lab (mSKIL)
Hemmer, Kathrin
Krömmelbein, Natascha
Seilheimer, Bernd
Dubuc, Jean-Emile
Antoine, Christophe
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > musculoSkeletal Innovative research Lab (mSKIL)
Language :
English
Title :
Reduction of Matrix Metallopeptidase 13 and Promotion of Chondrogenesis by Zeel T in Primary Human Osteoarthritic Chondrocytes
Publication date :
11 May 2021
Journal title :
Frontiers in Pharmacology
ISSN :
1663-9812
Publisher :
Frontiers, Switzerland
Special issue title :
Year 2020: New Trends in Pharmacological Treatments for Osteoarthritis
Anders S., Huber W., (2010). Differential expression analysis for sequence count data. Genome Biol. 11, R106. 10.1186/gb-2010-11-10-r106
Aury-Landas J., Bazille C., Allas L., Bouhout S., Chesneau C., Leclercq S., et al. (2017). Anti-inflammatory and chondroprotective effects of the S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A, in human articular chondrocytes. Sci. Rep. 7, 6483. 10.1038/s41598-017-06913-6
Bannuru R. R., Osani M. C., Vaysbrot E. E., Arden N. K., Bennell K., Bierma-Zeinstra S. M. A., et al. (2019). OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage 27, 1578–1589. 10.1016/j.joca.2019.06.011
Barr A. J., Conaghan P., (2013). Disease-modifying osteoarthritis drugs (DMOADs): what are they and what can we expect from them? Medicographia 35, 189–196. 10.1214/AOS/1013699998
Benjamini Y., Hochberg Y., (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodological) 57, 289–300. 10.1111/j.2517-6161.1995.tb02031.x
Benjamini Y., Yekutieli D., (2001). The control of the false discovery rate in multiple testing under dependency. Ann. Statist. 29, 1165–1188.
Chaitankar V., Karakülah G., Ratnapriya R., Giuste F. O., Brooks M. J., Swaroop A., (2016). Next generation sequencing technology and genomewide data analysis: perspectives for retinal research. Prog. Retin. Eye Res. 55, 1–31. 10.1016/j.preteyeres.2016.06.001
Chijiiwa M., Mochizuki S., Kimura T., Abe H., Tanaka Y., Fujii Y., et al. (2015). CCN1 (Cyr61) is overexpressed in human osteoarthritic cartilage and inhibits ADAMTS-4 (aggrecanase 1) activity. Arthritis Rheumatol. 67, 1557–1567. 10.1002/art.39078
Comblain F., Dubuc J. E., Lambert C., Sanchez C., Lesponne I., Serisier S., et al. (2016). Identification of targets of a new nutritional mixture for osteoarthritis management composed by curcuminoids extract, hydrolyzed collagen and green tea extract. PLoS One 11, e0156902. 10.1371/journal.pone.0156902
Geenen R., Overman C. L., Christensen R., Åsenlöf P., Capela S., Huisinga K. L., et al. (2018). EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann. Rheum. Dis. 77, 797–807. 10.1136/annrheumdis-2017-212662
Gottwald R., Weiser M., (2000). Treatment of osteoarthritis of the knee with Zeel T. Med. Biol. 13, 109–113.
Gouze J.-N., Gouze E., Popp M. P., Bush M. L., Dacanay E. A., Kay J. D., et al. (2006). Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res. Ther. 8, R173. 10.1186/ar2082
Hochberg Y., (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800–802. 10.1093/biomet/75.4.800
Holm S., (1979). A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6, 65–70. 10.2307/4615733
Hommel G., (1988). A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75, 383–386. 10.1093/biomet/75.2.383
Issekutz A. C., Mu J. Y., Liu G., Melrose J., Berg E. L., (2001). E-selectin, but not P-selectin, is required for development of adjuvant-induced arthritis in the rat. Arthritis Rheum. 44, 1428–1437. 10.1002/1529-0131(200106)44:6<1428::aid-art238>3.0.co;2-u
James C. G., Ulici V., Tuckermann J., Underhill T. M., Beier F., (2007). Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development. BMC Genomics 8, 205. 10.1186/1471-2164-8-205
Kraus V. B., Blanco F. J., Englund M., Karsdal M. A., Lohmander L. S., (2015). Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis and Cartilage 23, 1233–1241. 10.1016/j.joca.2015.03.036
Labarca C., Paigen K., (1980). A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102, 344–352. 10.1016/0003-2697(80)90165-7
Lesiak A., Gottwald R., Weiser M., (2001). The effectiveness of Zeel T treatment in intraarticular and intramuscular injections in osteoarthritis [in Polish]. Medyzyna Biol. 2, 30–36.
Li H., Wang D., Yuan Y., Min J., (2017). New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis. Arthritis Res. Ther. 19, 248. 10.1186/s13075-017-1454-2
Li J., Hou R., Niu X., Liu R., Wang Q., Wang C., et al. (2016). Comparison of microarray and RNA-Seq analysis of mRNA expression in dermal mesenchymal stem cells. Biotechnol. Lett. 38, 33–41. 10.1007/s10529-015-1963-5
Liu Y., Morley M., Brandimarto J., Hannenhalli S., Hu Y., Ashley E. A., et al. (2015). RNA-Seq identifies novel myocardial gene expression signatures of heart failure. Genomics 105, 83–89. 10.1016/j.ygeno.2014.12.002
Love M. I., Huber W., Anders S., (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. 10.1186/s13059-014-0550-8
Malone D. G., Dolan P. W., Brown R. R., Kalayoglu M. V., Arend R. A., Byrne G. I., et al. (1994). Interferon gamma induced production of indoleamine 2,3 dioxygenase in cultured human synovial cells. J. Rheumatol. 21, 1011–1019.
Mathy-Hartert M., Jacquemond-Collet I., Priem F., Sanchez C., Lambert C., Henrotin Y., (2009). Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm. Res. 58, 899–908. 10.1007/s00011-009-0063-1
Oh C. D., Maity S. N., Lu J. F., Zhang J., Liang S., Coustry F., et al. (2010). Identification of SOX9 interaction sites in the genome of chondrocytes. PLoS One 5, e10113. 10.1371/journal.pone.0010113
Pesesse L., Sanchez C., Delcour J.-P., Bellahcène A., Baudouin C., Msika P., et al. (2013). Consequences of chondrocyte hypertrophy on osteoarthritic cartilage: potential effect on angiogenesis. Osteoarthritis and Cartilage 21, 1913–1923. 10.1016/j.joca.2013.08.018
Pesesse L., Sanchez C., Walsh D. A., Delcour J.-P., Baudouin C., Msika P., et al. (2014). Bone sialoprotein as a potential key factor implicated in the pathophysiology of osteoarthritis. Osteoarthritis and Cartilage 22, 547–556. 10.1016/j.joca.2014.01.010
Rausch Osthoff A.-K., Niedermann K., Braun J., Adams J., Brodin N., Dagfinrud H., et al. (2018). 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann. Rheum. Dis. 77, 1251–1260. 10.1136/annrheumdis-2018-213585
Sanchez C., Mateus M. M., Defresne M. P., Crielaard J. M., Reginster J. Y., Henrotin Y. E., (2002). Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1beta and nonsteroidal antiinflammatory drugs. J. Rheumatol. 29, 772–782.
Sanchez C., Deberg M. A., Piccardi N., Msika P., Reginster J.-Y. L., Henrotin Y. E., (2005). Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1β and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis and Cartilage 13, 979–987. 10.1016/j.joca.2005.03.008
Spaapen F., van den Akker G. G., Caron M. M., Prickaerts P., Rofel C., Dahlmans V. E., et al. (2013). The immediate early gene product EGR1 and polycomb group proteins interact in epigenetic programming during chondrogenesis. PLoS One 8, e58083. 10.1371/journal.pone.0058083
Stancikova M., (1999). Inhibition of leukocyte elastase activity in vitro with Zeel T, Zeel comp., and their various potentiated constituents. Biol. Medizin 28, 83–84.
Wang C., Gong B., Bushel P. R., Thierry-Mieg J., Thierry-Mieg D., Xu J., et al. (2014). The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance. Nat. Biotechnol. 32, 926–932. 10.1038/nbt.3001
Wong M., Kireeva M. L., Kolesnikova T. V., Lau L. F., (1997). Cyr61, product of a growth factor-inducible immediate-early gene, regulates chondrogenesis in mouse limb bud mesenchymal cells. Developmental Biol. 192, 492–508. 10.1006/dbio.1997.8766
